Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Wearable Core Body Temperature Monitoring for Early Detection of Cytokine Release Syndrome in Outpatients Receiving CAR T-Cell Therapy

2 de novembro de 2026 atualizado por: Wake Forest University Health Sciences

A Randomized Controlled Trial of a Wearable Core Body Temperature Sensor Versus Standard Temperature Monitoring for Early Detection of Cytokine Release Syndrome in Patients Undergoing CAR T-Cell Therapy in an Outpatient Setting

The purpose of this research study is to see if a wearable temperature monitoring patch can detect cytokine release syndrome earlier than traditional oral temperature monitoring.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Descrição detalhada

This randomized pilot study is designed to evaluate the efficacy of a continuous temperature-monitoring wearable patch in patients receiving CAR-T therapy in the outpatient setting, comparing its performance to standard institutional monitoring protocols.

Tipo de estudo

Intervencional

Inscrição (Estimado)

105

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

    • North Carolina
      • Charlotte, North Carolina, Estados Unidos, 28204
      • Winston-Salem, North Carolina, Estados Unidos, 27103
        • Atrium Health Wake Forest Baptist Comprehensive Cancer Center
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

Patients:

  1. Ability to understand and willingness to sign an IRB-approved informed consent
  2. Age ≥ 18 years at the time of consent
  3. Scheduled to undergo CAR-T therapy in the outpatient setting at AHWFBCCC
  4. Ability to read and understand the English and/or Spanish language
  5. As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study
  6. Access to a mobile device for the duration of the trial

Provider/Staff:

Provider/staff participants must meet all of the following inclusion criteria to participate in the study:

  1. Verbally agree to participate
  2. Hospital at Home outpatient provider/advanced practice provider/nurse of at least one patient participant enrolled on Arm A who completed 14 days of temperature monitoring

Exclusion Criteria:

Patients:

  1. Planned prophylactic tocilizumab for mitigation of CRS as documented in the clinical trials pathway submission
  2. History of silicone allergy
  3. History of Medical Adhesive-Related Skin Injury (MARSI)
  4. Known skin condition that might preclude safe application of the patch, in the opinion of the enrolling investigator

Provider/Staff:

None

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Cuidados de suporte
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Outro: Arm A: TempShield Continuous Temperature Monitoring plus SOC Temperature Monitoring

Standard of care oral temperature monitoring plus TempShield continuous temperature monitoring patch

Patient participants will receive instruction from a research designee regarding use of the TempShield patch and smartphone application for continuous at-home temperature monitoring. Patient participants will complete onboarding of the application on their smartphone with assistance from the research designee, if necessary. Patient participants should place the patch immediately after completion of CAR-T infusion in the outpatient setting, with assistance from the research designee.

Outro: Arm B: SOC Temperature Monitoring

Standard of care oral temperature monitoring

Standard of care oral temperature monitoring

Sem intervenção: Arm C: Provider/Staff

Providers/staff are Hospital at Home personnel who support patients undergoing outpatient CAR-T therapy and who have monitored at least one participant enrolled on Arm A of the study.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Time to first recorded temperature elevation indicative of Cytokine Release Syndrome (CRS)
Prazo: From the initiation of CAR-T infusion up to Day 14 post-infusion.

Time (in hours) from the initiation of CAR-T infusion to the first occurrence of a recorded body temperature elevation of ≥ 100.4°F (38.0°C) during the 14-day post-CAR-T observation period. Participants who do not experience this defined temperature elevation within the 14 days will be censored at the time of their last recorded temperature reading during this window. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Incidence of temperature elevation indicative of Cytokine Release Syndrome (CRS)
Prazo: From the initiation of CAR-T infusion up to Day 14 post-infusion.

Number of participants who experience at least one recorded body temperature elevation of ≥ 100.4°F (38.0°C) during the 14-day post-CAR-T observation period. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
Incidence of high-grade (grade 2 or higher) Cytokine Release Syndrome (CRS)
Prazo: From the initiation of CAR-T infusion up to Day 14 post-infusion.

Number of participants who experience grade 2 or higher CRS during the 14-day post-CAR-T observation period. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
Time to resolution of Cytokine Release Syndrome (CRS) from temper elevation indicative of CRS (temperature ≥ 100.4 °F)
Prazo: From the temperature elevation (≥ 100.4 °F) to resolution during the 14 days after CAR-T infusion.

Time (in hours) from the from onset of fever indicative of CRS (temperature ≥ 100.4 °F) during the 14-day post-CAR-T observation period to resolution (i.e., when the participant no longer meets the CRS diagnostic criteria). If a participant experiences multiple episodes of CRS during the 14-day post-CAR-T observation period, the duration can be calculated per episode and cumulatively. This will be calculated for participants experiencing CRS (temperature ≥ 100.4 °F) during the 14-day post-CAR-T observation period. Reported by arm.

From the temperature elevation (≥ 100.4 °F) to resolution during the 14 days after CAR-T infusion.
Time to intervention after fever detection (temperature ≥ 100.4 °F)
Prazo: From the temperature elevation (≥ 100.4 °F) to intervention during the 14 days after CAR-T infusion.

Time (in hours) from documented temperature elevation of ≥ 100.4° F to clinician intervention (e.g., supportive care, medication followed by observation, etc.). This will be calculated for participants experiencing CRS during the 14-day post-CAR-T observation period. Reported by arm.

From the temperature elevation (≥ 100.4 °F) to intervention during the 14 days after CAR-T infusion.
Incidence of admission to the Intensive Care Unit (ICU) due to temperature elevation indicative of CRS
Prazo: From the initiation of CAR-T infusion up to Day 14 post-infusion.

Number of participants admitted to the ICU due to temperature elevation indicative of CRS during the 14-day post-CAR-T observation period. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
Time to discharge after admission to the Intensive Care Unit (ICU)
Prazo: From the initiation of CAR-T infusion up to Day 14 post-infusion.

Time (in hours) from ICU admission to ICU discharge. If a participant has multiple ICU admissions during the 14-day post-CAR-T observation period, the duration will be calculated cumulatively. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
Length of hospital stay
Prazo: From the initiation of CAR-T infusion up to Day 14 post-infusion.

Number of inpatient nights from hospital admission to hospital discharge due to temperature elevation indicative of CRS during the 14-day post-CAR-T observation period. If a participant has multiple hospital admissions due to CRS during the 14-day post-CAR-T observation period, the duration reported will be cumulative across all stays. This endpoint will be calculated for participants admitted to this hospital during the 14-day post-CAR-T observation period due to temperature elevation indicative of CRS. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
Incidence of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Prazo: From the initiation of CAR-T infusion up to Day 14 post-infusion.

Number of participants experiencing ICANS during the 14-day post-CAR-T observation period. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
Largest change in body temperature from baseline recorded during the 14-day post-CAR-T observation period
Prazo: From the initiation of CAR-T infusion up to Day 14 post-infusion.

The maximum numerical difference in body temperature recorded from baseline during the 14-day post-CAR-T observation period. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
The proportion of hours during the 14-day post CAR-T observation period when patch was worn
Prazo: From the initiation of CAR-T infusion up to Day 14 post-infusion.

The proportion of hours during the 14-day post-CAR-T observation period in which at least one valid human body temperature reading (86 °F to 108 °F) was recorded by the wearable patch, defined as Total adherence = (Number of hours with at least one valid temperature reading)/(24*14 hours). This will be calculated for participants randomized to wear the remote temperature monitoring device.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
The proportion of paired temperature readings from the temperature patch and an oral thermometer within one degree Fahrenheit in a five-minute window during the 14-day post-CAR-T observation period
Prazo: From the initiation of CAR-T infusion up to Day 14 post-infusion.

The number 5-minute intervals in the 14-day post-CAR-T observation period (from the first patch reading indicating a temperature from 86 °F to 108 °F), when concordance between the temperature patch and an oral thermometer within one degree Fahrenheit was observed.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
Patient satisfaction with CAR-T temperature monitoring methods
Prazo: The Day 14 post-infusion (+28 days) study calendar visit.

Patient satisfaction as assessed by the study survey, evaluating satisfaction on a Likert scale where higher scores indicate a higher level of patient satisfaction with the assigned monitoring method (standard of care vs. wearable patch).

The Day 14 post-infusion (+28 days) study calendar visit.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Cindy Varga, MD, Wake Forest University Health Sciences

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de dezembro de 2026

Conclusão Primária (Estimado)

1 de agosto de 2028

Conclusão do estudo (Estimado)

2 de janeiro de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

26 de outubro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

26 de outubro de 2026

Primeira postagem (Real)

2 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

5 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

2 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever